within Pharmacolibrary.Drugs.ATC.C;

model C07AB08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.0046,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009166666666666667,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Celiprolol is a selective beta-1 adrenergic receptor antagonist with partial agonist activity at beta-2 receptors. It is used primarily as an antihypertensive agent for the treatment of high blood pressure. Celiprolol is approved for use in several countries, particularly in Europe, but not in the United States.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, mostly male, after single oral dosing.</p><h4>References</h4><ol><li><p>Sonoda, J, et al., &amp; Shimodozono, Y (2021). Impact of green tea intake on the pharmacokinetics of celiprolol in healthy subjects. <i>International journal of clinical pharmacology and therapeutics</i> 59(3) 198–201. DOI:<a href=&quot;https://doi.org/10.5414/CP203795&quot;>10.5414/CP203795</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33210993/&quot;>https://pubmed.ncbi.nlm.nih.gov/33210993</a></p></li><li><p>Ieiri, I, et al., &amp; Sugiyama, Y (2012). Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. <i>Journal of clinical pharmacology</i> 52(7) 1078–1089. DOI:<a href=&quot;https://doi.org/10.1177/0091270011408612&quot;>10.1177/0091270011408612</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21593283/&quot;>https://pubmed.ncbi.nlm.nih.gov/21593283</a></p></li><li><p>Schmidt, P, et al., &amp; Deutsch, E (1985). [Comparative pharmacokinetics of the beta-1 receptor blookader celiprolol after a single oral administration in subjects with health kidneys and in patients with impaired renal function]. <i>Wiener klinische Wochenschrift</i> 97(18) 729–732. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2866633/&quot;>https://pubmed.ncbi.nlm.nih.gov/2866633</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AB08;
